

Dejan Juric

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8609575/publications.pdf>

Version: 2024-02-01

141
papers

8,750
citations

126907

33
h-index

48315

88
g-index

145
all docs

145
docs citations

145
times ranked

12922
citing authors

#	ARTICLE	IF	CITATIONS
1	Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 1929-1940.	27.0	1,582
2	COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. <i>Nature</i> , 2021, 595, 107-113.	27.8	537
3	Convergent loss of PTEN leads to clinical resistance to a PI(3)K inhibitor. <i>Nature</i> , 2015, 518, 240-244.	27.8	486
4	Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with <i>FGFR2</i> Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 252-263.	9.4	384
5	CDK 4/6 Inhibitors Sensitize <i>PIK3CA</i> Mutant Breast Cancer to PI3K Inhibitors. <i>Cancer Cell</i> , 2014, 26, 136-149.	16.8	375
6	Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. <i>Nature Medicine</i> , 2019, 25, 1415-1421.	30.7	359
7	Phosphatidylinositol 3-Kinase Inhibitor Selective Inhibition With Alpelisib (BYL719) in <i>PIK3CA</i> -Altered Solid Tumors: Results From the First-in-Human Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1291-1299.	1.6	298
8	Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2141-2148.	1.6	283
9	A Phase Ib Study of Alpelisib (BYL719), a PI3K-Specific Inhibitor, with Letrozole in ER+/HER2 ⁻ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 26-34.	7.0	268
10	AXL Mediates Resistance to PI3K Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. <i>Cancer Cell</i> , 2015, 27, 533-546.	16.8	263
11	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with <i>FGFR2</i> Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	9.4	254
12	mTORC1 Inhibition Is Required for Sensitivity to PI3K p110 Inhibitors in <i>PIK3CA</i> -Mutant Breast Cancer. <i>Science Translational Medicine</i> , 2013, 5, 196ra99.	12.4	251
13	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. <i>Cancer Discovery</i> , 2021, 11, 1913-1922.	9.4	243
14	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. <i>Cell Reports</i> , 2016, 17, 2367-2381.	6.4	215
15	Temporal and spatial heterogeneity of host response to SARS-CoV-2 pulmonary infection. <i>Nature Communications</i> , 2020, 11, 6319.	12.8	203
16	Alpelisib Plus Fulvestrant in <i>PIK3CA</i> -Altered and <i>PIK3CA</i> -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, e184475.	7.1	187
17	Alpelisib plus fulvestrant in <i>PIK3CA</i> -mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study. <i>Lancet Oncology</i> , The, 2021, 22, 489-498.	10.7	157
18	PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3K Inhibitors in Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 72-85.	9.4	154

#	ARTICLE	IF	CITATIONS
19	Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. <i>Cell Chemical Biology</i> , 2019, 26, 1067-1080.e8.	5.2	151
20	Cell Atlas of The Human Fovea and Peripheral Retina. <i>Scientific Reports</i> , 2020, 10, 9802.	3.3	145
21	Cancer Cell Profiling by Barcoding Allows Multiplexed Protein Analysis in Fine-Needle Aspirates. <i>Science Translational Medicine</i> , 2014, 6, 219ra9.	12.4	142
22	Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. <i>Cancer Discovery</i> , 2017, 7, 704-715.	9.4	127
23	Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer. <i>Science Signaling</i> , 2014, 7, ra29.	3.6	123
24	Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers. <i>Cancer Discovery</i> , 2020, 10, 86-103.	9.4	100
25	Deep learning enables genetic analysis of the human thoracic aorta. <i>Nature Genetics</i> , 2022, 54, 40-51.	21.4	90
26	Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2021, 11, 2436-2445.	9.4	69
27	A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3K β Isoform Inhibitor, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 5015-5023.	7.0	65
28	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	6.3	59
29	A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9051-9051.	1.6	52
30	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 α -) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1006-1006.	1.6	52
31	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2462-2470.	7.0	51
32	Single-cell barcode analysis provides a rapid readout of cellular signaling pathways in clinical specimens. <i>Nature Communications</i> , 2018, 9, 4550.	12.8	47
33	Small cell transformation of ROS1 fusion-positive lung cancer resistant to ROS1 inhibition. <i>Npj Precision Oncology</i> , 2020, 4, 21.	5.4	36
34	Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, , 1-8.	4.9	36
35	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	12.8	35
36	Safety, pharmacokinetics, and preliminary activity of the β -specific PI3K inhibitor BYL719: Results from the first-in-human study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2531-2531.	1.6	34

#	ARTICLE	IF	CITATIONS
37	First data for sotorasib in patients with pancreatic cancer with <i>KRAS</i> p.G12C mutation: A phase I/II study evaluating efficacy and safety. <i>Journal of Clinical Oncology</i> , 2022, 40, 360490-360490.	1.6	34
38	Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer. <i>Nature Communications</i> , 2021, 12, 3199.	12.8	33
39	EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 1378-1395.	9.4	33
40	First-in-class human trial of the PI3K-selective inhibitor SAR260301 in patients with advanced solid tumors. <i>Cancer</i> , 2018, 124, 315-324.	4.1	29
41	Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic Guidance. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1413-1419.	5.0	28
42	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1057-1057.	1.6	27
43	Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer. <i>Npj Precision Oncology</i> , 2019, 3, 18.	5.4	25
44	A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degradar, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5760-5770.	7.0	25
45	Ribociclib (LEE011) and letrozole in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): Phase Ib safety, preliminary efficacy and molecular analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 568-568.	1.6	25
46	A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. <i>BMC Cancer</i> , 2017, 17, 646.	2.6	24
47	Patient-Reported Outcomes in Patients With <i>PIK3CA</i> -Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. <i>Journal of Clinical Oncology</i> , 2021, 39, 2005-2015.	1.6	23
48	Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with <i>PIK3CA</i> -Mutant Cancers. <i>Clinical Cancer Research</i> , 2021, 27, 447-459.	7.0	22
49	Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 1018-1018.	1.6	22
50	Ph IB study of LEE011 and BYL719 in combination with letrozole in ER+, HER2- breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 143-143.	1.6	19
51	Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 103.	5.2	17
52	Rising Circulating Tumor DNA As a Molecular Biomarker of Early Disease Progression in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1246-1262.	3.0	16
53	A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. <i>Investigational New Drugs</i> , 2020, 38, 1483-1494.	2.6	15
54	Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with <i>PIK3CA</i> -mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1040-1040.	1.6	15

#	ARTICLE	IF	CITATIONS
55	A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 605-613.	2.5	14
56	Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for treatment-refractory hormone-receptor positive (HR+)/HER2- metastatic breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1004-1004.	1.6	14
57	Abstract 2638: Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triple-negative breast cancer (TNBC): Translational investigation. <i>Cancer Research</i> , 2022, 82, 2638-2638.	0.9	14
58	Phase Ib study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2 ⁻ BC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 533-533.	1.6	13
59	SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2 ⁻ advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS618-TPS618.	1.6	13
60	Phase Ib trial to evaluate safety and anti-tumor activity of the AKT inhibitor, ipatasertib, in combination with endocrine therapy and a CDK4/6 inhibitor for patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) (TAKTIC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1066-1066.	1.6	13
61	Identification of Somatic Acquired <i>BRCA1/2</i> Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4852-4862.	7.0	12
62	Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 127.	17.0	12
63	Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3404-3413.	7.0	10
64	A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2517-2517.	1.6	10
65	Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 1020-1020.	1.6	10
66	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. , 2021, 9, e002886.		9
67	A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2568-2568.	1.6	9
68	A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2519-2519.	1.6	9
69	Phase I dose escalation of H3B-6545, a first-in-class highly Selective ER [±] Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 1059-1059.	1.6	9
70	BYLieve: A phase II study of alpelisib (ALP) with fulvestrant (FUL) or letrozole (LET) for treatment of PIK3CA mutant, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2 ⁻) advanced breast cancer (aBC) progressing on/after cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS1107-TPS1107.	1.6	8
71	Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor. <i>Investigational New Drugs</i> , 2019, 37, 271-281.	2.6	7
72	High-Content Biopsies Facilitate Molecular Analyses and Do Not Increase Complication Rates in Patients With Advanced Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 1, 1-9.	3.0	6

#	ARTICLE	IF	CITATIONS
73	A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1111-TPS1111.	1.6	6
74	A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinstat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2547-2547.	1.6	6
75	Palliative care referrals in patients with advanced cancer on early-phase cancer clinical trials (EP-CTs).. <i>Journal of Clinical Oncology</i> , 2020, 38, 29-29.	1.6	6
76	Vascular smooth muscle cell phenotype switching in carotid atherosclerosis. <i>JVS Vascular Science</i> , 2022, 3, 41-47.	1.1	6
77	Incidence of peripheral edema in patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 649-658.	2.5	5
78	Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13025-e13025.	1.6	5
79	First-in-human, phase I, dose-escalation study of selective PI3K α isoform inhibitor MLN1117 in patients (pts) with advanced solid malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2501-2501.	1.6	5
80	First-in-human phase I trial of the PI3K β -selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).. <i>Journal of Clinical Oncology</i> , 2015, 33, 2564-2564.	1.6	5
81	FGFR gene amplification and response to endocrine therapy in metastatic hormone receptor positive (HR+) breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 1013-1013.	1.6	5
82	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1028-1028.	1.6	5
83	A phase I open label study evaluating VT1021 in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS3158-TPS3158.	1.6	5
84	Phase Ib Study of the Histone Deacetylase 6 Inhibitor Citarinostat in Combination With Paclitaxel in Patients With Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 786120.	2.8	5
85	Abstract P1-17-10: H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study. <i>Cancer Research</i> , 2022, 82, P1-17-10-P1-17-10.	0.9	5
86	Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), <i>PIK3CA</i> -altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).. <i>Journal of Clinical Oncology</i> , 2021, 39, 1054-1054.	1.6	4
87	Tumor genomics and response to CDK 4/6 inhibitors for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 1046-1046.	1.6	4
88	Abstract P1-18-08: Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (<math>\geq 6\text{ mo}</math> or <math>\leq 6\text{ mo}</math>) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i> -mutated advanced breast cancer (ABC) from BYLieve.. <i>Cancer Research</i> , 2022, 82, P1-18-08-P1-18-08.	0.9	4
89	Abstract P5-13-03: Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), <i>PIK3CA</i> -mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study. <i>Cancer Research</i> , 2022, 82, P5-13-03-P5-13-03.	0.9	4
90	Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1052-1052.	1.6	4

#	ARTICLE	IF	CITATIONS
91	Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study.. Journal of Clinical Oncology, 2022, 40, 1006-1006.	1.6	4
92	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. Journal of Clinical Oncology, 2016, 34, LBA509-LBA509.	1.6	3
93	Phase 1b study of TAK-659 + nivolumab (nivo) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2018, 36, e15124-e15124.	1.6	3
94	Understanding the supportive care needs of early-phase cancer clinical trial (CT) participants.. Journal of Clinical Oncology, 2020, 38, 26-26.	1.6	3
95	Abstract P1-18-03: Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A. Cancer Research, 2022, 82, P1-18-03-P1-18-03.	0.9	3
96	Abstract P5-17-05: A phase I/II study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer. Cancer Research, 2022, 82, P5-17-05-P5-17-05.	0.9	3
97	Abstract PD15-01: Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial. Cancer Research, 2022, 82, P15-01-P15-01.	0.9	3
98	Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.. Journal of Clinical Oncology, 2022, 40, 1018-1018.	1.6	3
99	Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGF β 2 inhibitor, as monotherapy or in combination with cemiplimab in a phase I/1b study.. Journal of Clinical Oncology, 2021, 39, 2510-2510.	1.6	2
100	Supportive care services and goals of care in early phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2021, 39, 26-26.	1.6	2
101	401...Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. , 2020, , .		2
102	SU2C phase 1b study of the PI3K α inhibitor BYL719 with letrozole in ER+/HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2014, 32, 516-516.	1.6	2
103	Trial design of a first-in-human phase 1 evaluation of SY-1365, a first-in-class selective CDK7 inhibitor, with initial expansions in ovarian and breast cancer.. Journal of Clinical Oncology, 2018, 36, TPS2600-TPS2600.	1.6	2
104	Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) from SOLAR-1.. Journal of Clinical Oncology, 2019, 37, 1039-1039.	1.6	2
105	NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors.. Journal of Clinical Oncology, 2019, 37, 3043-3043.	1.6	2
106	369...Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers. , 2021, 9, A397-A397.		2
107	Abstract P1-17-03: H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, phase 1b study. Cancer Research, 2022, 82, P1-17-03-P1-17-03.	0.9	2
108	Abstract 1789: Chromatin modifier alterations confer resistance to endocrine deprivation and CDK4/6 inhibitors in ER+ breast cancer and drive convergent evolution in patient autopsy lesions. Cancer Research, 2022, 82, 1789-1789.	0.9	2

#	ARTICLE	IF	CITATIONS
109	Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer: Phase 1b clinical trial.. Journal of Clinical Oncology, 2017, 35, TPS1106-TPS1106.	1.6	1
110	A phase 1b study to evaluate TAK-659 in combination with nivolumab in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2017, 35, TPS3104-TPS3104.	1.6	1
111	Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with <i>PIK3CA</i>-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.. Journal of Clinical Oncology, 2019, 37, 1038-1038.	1.6	1
112	Comparison of the cell-free DNA genomics in patients with metastatic breast cancer (MBC) who develop brain metastases versus those without brain metastases.. Journal of Clinical Oncology, 2020, 38, 1094-1094.	1.6	1
113	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 2567-2567.	1.6	1
114	Abstract P2-07-02: Genomic predictors of rapid progression to first line endocrine and CDK4/6 inhibitor combination therapy in patients with estrogen receptor positive (ER+) HER-2 negative (HER2-) advanced breast cancer (ABC). Cancer Research, 2022, 82, P2-07-02-P2-07-02.	0.9	1
115	Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation. Cancer Research, 2022, 82, 5162-5162.	0.9	1
116	Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy. JCO Precision Oncology, 2022, , .	3.0	1
117	Single-cell profiling of human heart and blood in immune checkpoint inhibitor-associated myocarditis.. Journal of Clinical Oncology, 2022, 40, 2507-2507.	1.6	1
118	Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, TPS4180-TPS4180.	1.6	1
119	Abstract PS18-19: Comparison of metastatic genomic profile in patients ≤ 45 years and patients >45 years with triple-negative breast cancer. , 2021, , .		0
120	Abstract PS17-02: Molecular alterations in the androgen receptor and associated clinical outcomes in hormone receptor-positive/HER2- metastatic breast cancer. , 2021, , .		0
121	Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.. Journal of Clinical Oncology, 2021, 39, TPS2667-TPS2667.	1.6	0
122	Identifying early-phase clinical trial (EP-CT) participants at risk for poor outcomes.. Journal of Clinical Oncology, 2021, 39, 301-301.	1.6	0
123	Time burden and logistical intensity of early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2021, 39, 84-84.	1.6	0
124	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 533-533.	1.6	0
125	Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review.. Journal of Clinical Oncology, 2013, 31, 145-145.	1.6	0
126	Phase I evaluation of the PI3 kinase (PI3K) inhibitor taselisib (GDC-0032) in multiple locally advanced or metastatic <i>PIK3CA</i> mutant solid tumor types.. Journal of Clinical Oncology, 2016, 34, TPS11621-TPS11621.	1.6	0

#	ARTICLE	IF	CITATIONS
127	Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase II results.. Journal of Clinical Oncology, 2016, 34, LBA509-LBA509.	1.6	0
128	Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS-Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109. Blood, 2016, 128, 2749-2749.	1.4	0
129	Molecular alterations in the Ras-Raf-Erk (MAPK) pathway in metastatic hormone receptor positive (HR+)/HER2- breast cancer: Incidence and impact on clinical outcomes.. Journal of Clinical Oncology, 2018, 36, 1021-1021.	1.6	0
130	Molecular characterization and monitoring of patient ctDNA in phase I study of H3B-6545 in ER+ MBC.. Journal of Clinical Oncology, 2019, 37, 1052-1052.	1.6	0
131	Involvement of social work services in patients with advanced cancer in early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2020, 38, 28-28.	1.6	0
132	Abstract P3-09-11: Clinical characteristics associated with <i>BRCA1/2</i> mutations identified on routine tumor tissue genotyping in metastatic breast cancer. Cancer Research, 2022, 82, P3-09-11-P3-09-11.	0.9	0
133	Abstract P5-13-18: Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies. Cancer Research, 2022, 82, P5-13-18-P5-13-18.	0.9	0
134	Abstract P1-18-22: AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation. Cancer Research, 2022, 82, P1-18-22-P1-18-22.	0.9	0
135	Abstract P1-18-07: Impact of <i>PIK3CA</i> mutation (<i>PIK3CA</i> -mt) clonality on alpelisib (ALP) activity based on real-world evidence (RWE) following liquid biopsy testing. Cancer Research, 2022, 82, P1-18-07-P1-18-07.	0.9	0
136	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. Neuro-Oncology, 2021, 23, vi49-vi49.	1.2	0
137	Utilizing Natural Language Processing (NLP) to identify breast cancer associated-lung metastases from pathology reports to delineate characteristics and challenges of this common site of breast cancer recurrence.. Journal of Clinical Oncology, 2022, 40, e13592-e13592.	1.6	0
138	Relationship of travel distance with patient demographics, advance care planning, and survival in early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2022, 40, 6558-6558.	1.6	0
139	Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.. Journal of Clinical Oncology, 2022, 40, 3084-3084.	1.6	0
140	Protocol requirements and logistical intensity of early-phase clinical trials (EP-CTs).. Journal of Clinical Oncology, 2022, 40, e18609-e18609.	1.6	0
141	Patient-reported hope, quality of life (QOL), symptom burden, and coping mechanisms in early phase clinical trial participants.. Journal of Clinical Oncology, 2022, 40, 12114-12114.	1.6	0